Assessing the feasibility of a sea otter reintroduction to Oregon through a coupled natural-human lens

Sea otters fulfill a keystone role in several Northeastern Pacific nearshore ecosystems. However, their influence has been absent in Oregon coastal waters since their extirpation in the 19th and early 20th century. Interest has been growing for a translocation attempt to reintroduce sea otters to Oregon from one or more source populations of the southern sea otter and northern sea otter subspecies. Numerous unanswered questions require inquiry before a productive discussion can take place on the advisability of such an effort. A successful reintroduction would alter the existing coupled natural-human system dynamics between Oregon coastal communities, Oregon residents as a whole, and the nearshore environment. The appropriate source of reintroduction stock bears discussion, as do the optimal sites on the Oregon coast for a translocation effort and stakeholders’ attitudes towards such a proposal. This paper considers select issues related to the genetics, ecology, and human dimensions of a potential Oregon sea otter reintroduction, integrating insights from each discipline to provide a preliminary interdisciplinary examination

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Targeted therapies and the consequent adoption of "personalized" oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not reliant upon the same mechanisms as those which have been targeted). To address these limitations, an international task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a wide range of high-priority targets (74 in total) that could be modified to improve patient outcomes. For these targets, corresponding low-toxicity therapeutic approaches were then suggested, many of which were phytochemicals. Proposed actions on each target and all of the approaches were further reviewed for known effects on other hallmark areas and the tumor microenvironment. Potential contrary or procarcinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixed evidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of the relationships revealed potentially complementary effects, and the remainder had no known relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. This novel approach has potential to be relatively inexpensive, it should help us address stages and types of cancer that lack conventional treatment, and it may reduce relapse risks. A proposed agenda for future research is offered

JET experiments with tritium and deuterium–tritium mixtures

Extensive preparations are now underway for an experiment in the Joint European Torus (JET) using tritium and deuterium–tritium mixtures. The goals of this experiment are described as well as the progress that has been made in developing plasma operational scenarios and physics reference pulses for use in deuterium–tritium and full tritium plasmas. At present, the high performance plasmas to be tested with tritium are based on either a conventional ELMy H-mode at high plasma current and magnetic field (operation at up to 4 MA and 4 T is being prepared) or the so-called improved H-mode or hybrid regime of operation in which high normalised plasma pressure at somewhat reduced plasma current results in enhanced energy confinement. Both of these regimes are being re-developed in conjunction with JET's ITER-like Wall (ILW) of beryllium and tungsten. The influence of the ILW on plasma operation and performance has been substantial. Considerable progress has been made on optimising performance with the all-metal wall. Indeed, operation at the (normalised) ITER reference confinement and pressure has been re-established in JET albeit not yet at high current. In parallel with the physics development, extensive technical preparations are being made to operate JET with tritium. The state and scope of these preparations is reviewed, including the work being done on the safety case for DT operation and on upgrading machine infrastructure and diagnostics. A specific example of the latter is the planned calibration at 14 MeV of JET neutron diagnostics

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Targeted therapies and the consequent adoption of "personalized" oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not reliant upon the same mechanisms as those which have been targeted). To address these limitations, an international task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a wide range of high-priority targets (74 in total) that could be modified to improve patient outcomes. For these targets, corresponding low-toxicity therapeutic approaches were then suggested, many of which were phytochemicals. Proposed actions on each target and all of the approaches were further reviewed for known effects on other hallmark areas and the tumor microenvironment. Potential contrary or procarcinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixed evidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of the relationships revealed potentially complementary effects, and the remainder had no known relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. This novel approach has potential to be relatively inexpensive, it should help us address stages and types of cancer that lack conventional treatment, and it may reduce relapse risks. A proposed agenda for future research is offered.Multiple funders. See acknowledgments within article for details.This is the final version of the article. It first appeared from Elsevier via http://dx.doi.org/10.1016/j.semcancer.2015.09.00